A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.
Zhu L, Retana D, Garcia-Gomez P, Alvaro-Espinosa L, Priego N, Masmudi-Martin M, Yebra N, Miarka L, Hernandez-Encinas E, Blanco-Aparicio C, Martinez S, Sobrino C, Ajenjo N, Artiga MJ, Ortega-Paino E, Torres-Ruiz R, Rodriguez-Perales S, Soffietti R, Bertero L, Cassoni P, Weiss T, Munoz J, Sepulveda JM, Gonzalez-Leon P, Jimenez-Roldan L, Moreno LM, Esteban O, Perez-Nunez A, Hernandez-Lain A, Toldos O, Ruano Y, Alcazar L, Blasco G, Fernandez-Alen J, Caleiras E, Lafarga M, Megias D, Grana-Castro O, Nor C, Taylor MD, Young LS, Vareslija D, Cosgrove N, Couch FJ, Cusso L, Desco M, Mouron S, Quintela-Fandino M, Weller M, Pastor J, Valiente M
EMBO Mol Med. 2022 Mar 7;14(3):e14552. doi: 10.15252/emmm.202114552. Epub 2022 Feb 17.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
No plasmids are currently publicly available from Addgene for this article.